Compare Kroger Co (KR) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs McKesson Corporation — how do they compare? Kroger Co trades at $61.64 (market cap $36.27B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 3× Kroger Co's market cap, and Kroger Co pays the higher dividend (2.54%). Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 108 Days and McKesson Corporation for 74 Days on average.
| KR | MCK | |
|---|---|---|
Market Cap | $36.27B | $108.46B |
Volume | 8,301,523 | 712,607 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $995.69 |
52-Week Low | $55.53 | $725.17 |
Typical Hold Time | 108 Days | 74 Days |
Enterprise Value | $57.69B | $115.00B |
Dividend Yield | 2.54% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $61.41, up 3.65% with a bullish technical signal and positive analyst sentiment. The stock shows strong fundamentals with $147.12B revenue, 23.11% gross margins, and consistent dividend payments. Recent earnings beat expectations in Q2 2026, while Q1 2026 slightly missed. Technical indicators show the stock trading near pivot point resistance at $62 with solid support at $59-60 levels. The company maintains robust cash flow generation with $5.79B from operations in 2025.
Kroger presents a compelling investment case with attractive valuation (P/S 0.26), strong analyst support (47.72% buy ratings), and $70.62 consensus price target offering 15% upside. Key risks include integration challenges with Giant Eagle acquisition, cost pressures affecting 2026 margins, and competitive threats from Walmart. The stock's digital growth initiatives and retail media expansion provide growth catalysts, though investors should monitor identical sales performance and acquisition integration progress.
McKesson (MCK) trades at $930.25, up 2.19% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins are thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing long-term visibility.
The outlook is positive, driven by operational strength and strategic partnerships, but investors face risks from margin pressure and drug pricing uncertainty. With 81% of analysts rating it Buy and a consensus target of $956.43, the stock offers upside, though high RSI levels suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
